- Report
- November 2024
- 65 Pages
Global
From €4474EUR$4,995USD£3,814GBP
- Report
- January 2025
- 110 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- May 2025
- 193 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- June 2025
- 72 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- October 2024
- 180 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- August 2024
- 53 Pages
Global
From €4474EUR$4,995USD£3,814GBP
- Report
- November 2024
- 80 Pages
North America
From €4434EUR$4,950USD£3,779GBP
- Report
- August 2023
- 405 Pages
South Africa
- Report
- January 2024
- 193 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- June 2021
- 55 Pages
Global
From €4474EUR$4,995USD£3,814GBP
- Report
- December 2022
- 59 Pages
China
From €4474EUR$4,995USD£3,814GBP
- Report
- December 2023
- 93 Pages
Global
From €3500EUR$4,186USD£3,088GBP

Contract dose manufacturing is a service provided by pharmaceutical companies to produce drugs and other pharmaceutical products. It involves the production of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) for customers. Contract dose manufacturing is a cost-effective way for pharmaceutical companies to outsource the production of their products. It also allows them to focus on their core competencies, such as research and development, while leaving the manufacturing to a third-party. Contract dose manufacturing is a highly regulated process, with strict quality control measures in place to ensure the safety and efficacy of the products.
Some of the companies in the contract dose manufacturing market include Boehringer Ingelheim, Catalent, Lonza, Patheon, Recipharm, and Vetter. Show Less Read more